Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD30 CAR-T cells (Shandong Qilu)
- Development stage
- Phase 1
- Lead developer
- Shandong Qilu Stem Cell Engineering
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CD30 CAR-T cells (Shandong Qilu) is an autologous chimeric antigen receptor (CAR) T-cell therapy being developed by Shandong Qilu Cell Therapy Engineering Technology Co., Ltd for the treatment of relapsed or refractory CD30-positive lymphomas, including classical Hodgkin lymphoma and anaplastic large cell lymphoma. The therapy involves the ex vivo genetic modification of a patient's own T cells to express a CAR that specifically targets CD30 (TNFRSF8), a transmembrane protein consistently overexpressed in these malignancies. Once re-infused into the patient, these engineered T cells recognize and bind to CD30-expressing tumor cells, leading to targeted cytotoxicity and tumor eradication. The product is currently undergoing Phase 1 clinical evaluation to assess its safety, tolerability, and preliminary efficacy in patients with CD30-positive relapsed/refractory lymphoma.
- Other names
- CD30-targeted chimeric antigen receptor T-cell therapyCD-30-targeted chimeric antigen receptor T-cell therapyCD 30-targeted chimeric antigen receptor T-cell therapyautologous CD30 CAR-T cellschimeric antigen receptor gene modified T cells
02
Targets
CD30 (CD30 antigen)
Beyond the preview
Go deeper on CD30 CAR-T cells (Shandong Qilu).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD30 CAR-T cells (Shandong Qilu).